J.W. Cole Advisors Inc. Has $515,000 Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

J.W. Cole Advisors Inc. lowered its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 61.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 6,526 shares of the company's stock after selling 10,449 shares during the period. J.W. Cole Advisors Inc.'s holdings in TransMedics Group were worth $515,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. FMR LLC grew its position in shares of TransMedics Group by 42.5% during the third quarter. FMR LLC now owns 4,714,870 shares of the company's stock worth $258,139,000 after acquiring an additional 1,407,171 shares during the last quarter. Vanguard Group Inc. grew its position in shares of TransMedics Group by 1.7% during the third quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company's stock worth $99,341,000 after acquiring an additional 29,798 shares during the last quarter. Eventide Asset Management LLC grew its position in TransMedics Group by 1,271.7% in the 3rd quarter. Eventide Asset Management LLC now owns 925,356 shares of the company's stock valued at $50,663,000 after buying an additional 857,895 shares in the last quarter. Bank of New York Mellon Corp grew its position in TransMedics Group by 91.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company's stock valued at $41,615,000 after buying an additional 363,012 shares in the last quarter. Finally, American Century Companies Inc. grew its position in TransMedics Group by 271.2% in the 3rd quarter. American Century Companies Inc. now owns 486,956 shares of the company's stock valued at $26,661,000 after buying an additional 355,755 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Insider Activity

In other news, CFO Stephen Gordon sold 15,000 shares of the company's stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $74.01, for a total value of $1,110,150.00. Following the transaction, the chief financial officer now owns 23,299 shares in the company, valued at approximately $1,724,358.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $74.01, for a total value of $1,110,150.00. Following the transaction, the chief financial officer now owns 23,299 shares in the company, valued at $1,724,358.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Tamer I. Khayal sold 15,512 shares of the stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total value of $1,403,060.40. Following the completion of the transaction, the insider now owns 25,185 shares in the company, valued at approximately $2,277,983.25. The disclosure for this sale can be found here. Insiders have sold 117,078 shares of company stock worth $9,972,971 in the last 90 days. Company insiders own 6.70% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Piper Sandler assumed coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They issued an "overweight" rating and a $95.00 target price for the company. JPMorgan Chase & Co. increased their target price on shares of TransMedics Group from $87.00 to $105.00 and gave the company an "overweight" rating in a research report on Tuesday, February 27th. Oppenheimer increased their target price on shares of TransMedics Group from $92.00 to $105.00 and gave the company an "outperform" rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley increased their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $102.00.

TransMedics Group Stock Down 1.9 %

Shares of TMDX traded down $1.72 during trading hours on Wednesday, reaching $88.88. The company's stock had a trading volume of 537,542 shares, compared to its average volume of 688,154. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of -117.66 and a beta of 1.99. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $99.63. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The company has a 50 day moving average of $82.95 and a two-hundred day moving average of $74.01.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.22. The company had revenue of $81.20 million for the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm's quarterly revenue was up 158.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.21) EPS. As a group, research analysts predict that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.